文献速递药物相互作用抗栓抗凝管理肝肾功能剂量调整

PBPK模型指导口服抗凝药与奈玛特韦/利托那韦起始用药的剂量管理

Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.
PubMed 文献 · Clin Pharmacol Ther · 2022-07-04

该研究应用PBPK建模模拟利托那韦与利伐沙班及外消旋华法林的药物相互作用。结果显示奈玛特韦/利托那韦升高利伐沙班暴露,肾功能不全老年人更显著,10 mg日剂量可维持可接受暴露;华法林S-浓度略降而R-浓度显著升高致INR下降,INR恢复需2周。

要点

  • 奈玛特韦/利托那韦升高利伐沙班暴露,肾功能不全老年人影响更显著。
  • 利伐沙班10 mg日剂量可维持治疗期间可接受的全身暴露。
  • 华法林INR下降且仅于停药2周后恢复,需延长INR监测。

核心结论

  • PBPK模拟显示奈玛特韦/利托那韦与利伐沙班及华法林存在临床重要但未经试验验证的药物相互作用。

研究设计与样本

  • 采用Simcyp Simulator进行生理药理学基于药代动力学(PBPK)建模模拟,化合物与群体模型取自Simcyp及既往研究。
  • 在验证利托那韦PBPK模型后,于一般人群(20-65岁)和老年受试者(65-85岁)中开展前瞻性DDI模拟,涵盖伴或不伴中度肾功能损害者。

主要发现

  • 奈玛特韦/利托那韦治疗下模拟利伐沙班浓度升高,肾功能损害的老年受试者影响更显著。
  • 停用奈玛特韦/利托那韦后第4天利伐沙班过度暴露恢复至正常范围,与酶活性恢复一致。
  • 利托那韦使模拟S-华法林浓度轻微下降,但R-华法林浓度显著升高,导致INR下降。
  • INR仅在奈玛特韦/利托那韦治疗后2周恢复,华法林需更长时间INR监测。

关键数值与推荐

  • 利伐沙班10 mg日剂量可在奈玛特韦/利托那韦治疗期间有效维持可接受的利伐沙班全身暴露。
  • 华法林INR于奈玛特韦/利托那韦治疗后2周仅恢复,支持延长INR监测。

临床怎么用

  • 对合并心血管疾病且需奈玛特韦/利托那韦的COVID-19患者,应基于PBPK模拟结果评估利伐沙班和华法林的DDI风险。
  • 利伐沙班治疗期间可考虑10 mg日剂量以维持可接受暴露,华法林治疗者需延长INR监测至停药后2周。

局限性

  • 本研究为PBPK模拟,未开展临床DDI试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases who are at higher risk of progressing to critical illness should be treated with nirmatrelvir/ritonavir (Paxlovid). Ritonavir, the booster in nirmatrelvir/ritonavir, modulates multiple drug metabolizing enzymes and transporters, complicating its use in real-world clinics. We aimed to apply physiologically-based pharmacokinetic (PBPK) modeling to simulate the complex drug-drug interactions (DDIs) of ritonavir with two anticoagulants, rivaroxaban and racemic warfarin, to address this important clinical conundrum. Simulations were implemented within Simcyp Simulator. Compound and population models were adopted from Simcyp and our previous studies. Upon verification and validation of the PBPK model of ritonavir, prospective DDI simulations with the anticoagulants were performed in both the general population (20-65 years) and geriatric subjects (65-85 years) with or without moderate renal impairment. Elevated rivaroxaban concentrations were simulated with nirmatrelvir/ritonavir treatment, where the impact was more profound among geriatric subjects with renal impairment. The overexposure of rivaroxaban was restored to normal range on day 4 post-discontinuation of nirmatrelvir/ritonavir, corroborating with the recovery of enzyme activity. A lower 10 mg daily dose of rivaroxaban could effectively maintain acceptable systemic exposure of rivaroxaban during nirmatrelvir/ritonavir treatment. Treatment of ritonavir marginally declined simulated S-warfarin concentrations, but substantially elevated that of R-warfarin, resulting in a decrease in the international normalized ratio (INR). As INR only recovered 2 weeks post-nirmatrelvir/ritonavir treatment, a longer surveillance INR for warfarin becomes important. Our PBPK-guided simulations evaluated clinically important yet untested DDIs and supports clinical studies to ensure proper anticoagulation management of patients with COVID-19 with chronic coagulative abnormalities when initiating nirmatrelvir/ritonavir therapy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang Z, Chan ECY. Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment. Clin Pharmacol Ther. 2022. PMID: 35712802. doi:10.1002/cpt.2687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。